MOVE: 18-month analysis points to palovarotene ‘evidence for efficacy’ in FOP
Palovarotene therapy reduces heterotopic ossification (HO) in children and adults with fibrodysplasia ossificans progressiva (FOP), indicates the third interim analysis of the MOVE trial, conducted after at least 18 months of follow-up.